FGFR2 fusions are common in a subset of cholangiocarcinoma and lung, breast, thyroid, and prostate adenocarcinoma (1–3) and rare in ovarian adenocarcinomas, while FGFR2 point mutations or gene amplification is more common (4, 5). This evidence concerns the gene FGFR2 and prostate adenocarcinoma.